Applied Filters
Eli Lilly wins mammoth cybersquatting case
Eli Lilly has won a cybersquatting case in which the company successfully ordered the transfer of more than 200 domain names that purported to offer discounted erectile dysfunction drugs.
Roche wins cybersquatting case
Roche has defeated a cybersquatter in a dispute centring on 18 domain names that infringed trademarks owned by the pharmaceutical company.
New fund to support Australian biomedical discoveries launches
A new fund dedicated to accelerate the development and commercialisation of Australian biomedical discoveries has officially launched.
Fujifilm signs influenza drug licensing deal
Japan-based Fujifilm has signed a patent licensing agreement with a Chinese company centring on an ingredient used in its anti-influenza drug Avigan.
Report predicts generic drugs will soar by 2020
The “Global Generic Drugs Market 2016-2020” report predicts that the expiry of patents for branded drugs, worth $150 billion, will allow generic companies to prosper by 2020.
Sequenom targets Ariosa in Australia
Sequenom has filed a patent infringement lawsuit against Sonic Healthcare, Australian Clinical Labs and Ariosa Diagnostics at the Australian Federal Court.
BIO 2016: Understanding innovation is key to success
For something to be innovative it must “add value” and companies must ensure they understand the term in order to succeed, the 2016 BIO International Convention has heard.
‘2016 State of Innovation Report’: Biotech innovation decreases by 2%
Biotech was the only technology area out of 12 studied that has shown a global decline in its year-on-year innovation, declining by 2%, according to the “2016 State of Innovation Report: Disruptive, Game-Changing Innovation” by Thomson Reuters.
Gilead gets Sovaldi patent approval in India despite opposition
Gilead has been granted a patent for its hepatitis C drug Sovaldi in India, despite concerns over the cost of the drug.
Australia criticised over ‘excessive’ protection for pharma patents
Australia’s patent system is “poorly targeted” and protection for pharmaceutical inventions is “excessive”, according to a government advisory committee.
